期刊文献+

不同配比头孢哌酮钠/舒巴坦对革兰阴性杆菌体外抗菌效果影响 被引量:6

Effect of Different Proportions of Cefoperazone / sulbactam against Gram-negative Bacteria in Vitro
下载PDF
导出
摘要 目的探讨头孢哌酮钠/舒巴坦75/30μg(SCF105)和75/75μg(SCF150)两种配比药敏纸片对革兰阴性杆菌的体外抗菌效果。方法用纸片扩散法检测SCF105和SCF150两种药敏纸片对临床分离的86株革兰阴性杆菌的抑菌环直径,比较药敏结果并分析两种药敏纸片对4种常见革兰阴性杆菌(铜绿假单胞菌、大肠埃希菌、肺炎克雷伯菌及鲍曼不动杆菌)的抗菌效果。结果本研究检测86株革兰阴性杆菌的敏感率和中介率SCF150纸片均高于SCF105纸片(P<0.01);SCF150纸片全部菌株的耐药率低于SCF105纸片(P<0.01)。对4种革兰阴性杆菌的敏感率SCF150纸片均高于SCF105纸片,其中差异最明显的是大肠埃希菌(P<0.05)。对全部菌株及4种革兰阴性杆菌抑菌环直径SCF105纸片均小于SCF150纸片(P<0.05)。4种革兰阴性杆菌抑菌环直径两两比较显示,SCF105纸片中大肠埃希菌与2种菌株(铜绿假单胞菌及鲍曼不动杆菌)以及SCF150纸片中大肠埃希菌与其他3种菌株抑菌环直径比较差异均有统计学意义(P<0.05)。结论成分配比为75/75μg的头孢哌酮钠/舒巴坦药敏低纯对革兰阴性杆菌的体外抗菌效果更优。 Objective To explore the differences of antibacterial effect in vitro between two different concentrations of Cefoperazone-Sulbactam( 2∶ 1 and 1∶ 1) 75 /30 μg( SCF105) and 75 /75 μg( SCF150) upon gram-negative bacilli. Methods Susceptibility test of 86 strains of clinical isolated gram-negative bacilli was conducted with K-B method using SCF105 and SCF150 respectively and the diameter of inhibition zone were measured. The Susceptibility results of two kinds of susceptibility sheets were analyzed and the antimicrobial results on the four common gram-negative bacillus( Pseudomonas aeruginosa,e. Coli,klebsiella pneumoniae and acinetobacter baumannii) was explored. Results For all the 86 strains,susceptibility rate and intermediate rate SCF 150 disc were 53. 5% and 26. 7%,which were significantly higher than that with SCF105 disc; the resistance rate with SCF disc was 19. 7%,significantly lower than the resistance rate of SCF105 disc( P〈0. 01). Wilcox on signed rank sum test for the four kinds of clinical common gram negative bacterium( Pseudomonas aeruginosa,Escherichia coli,Klebsiella pneumoniae and Acinetobacter baumannii) was used and sensitivity rate with SCF150 disc was higher than the result of SCF105 disc,and the difference was significant,E. Coli( P〈0. 05); For all strains and four gram negative bacteria,the inhibitor diameter of SCF105 disc was smaller than that of SCF150 disc( P〈0. 05),and especially in E. coli( P〈0. 05). Compared with the inhibitor diameter 4 kinds gram-negative bacilli,there were significant differences between SCF105 of E. Coli and Pseudomonas aeruginosa and acinetobacter baumannii); meanwhile,there were significant differences between SCF150 of E. coli and 3 other kinds( P〈0. 05). Conclusion AS far as antibacterial effectiveness of gram-negative bacilli in vitro is concerned,composition ratio of 75 /75 μg Cefoperazone-Sulbactam is superior to that of 75 /30 μg Cefoperazone-Sulbactam.
出处 《临床误诊误治》 2015年第12期102-104,共3页 Clinical Misdiagnosis & Mistherapy
基金 石家庄市科学技术研究与发展计划项目(11146423)
关键词 头孢哌酮/舒巴坦 革兰阴性杆菌 药敏试验 纸片扩散法 Cefoperazone-Sulbactam Gram-negative bacterium Drug sensitive test Disc diffusion method
  • 相关文献

参考文献8

  • 1汪复,朱德妹,胡付品,阮斐怡,倪语星,孙景勇,徐英春,孙宏莉,胡云健,艾效曼,俞云松,杨青,孙自镛,简翠,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,薛建昌,张泓,李万华.2007年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2008,8(5):325-333. 被引量:305
  • 2卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团重庆出版社,2009:700-701.
  • 3Clinical and Laboratory Standards Institute. M2-A9 Per- formance standards for antimicrobial disk susceptibility tests-Eleventh edition: Approved standard [ D ]. Wayne, PA: Clinical and Laboratory StandardsInstitute, 2012.
  • 4Clinical and Laboratory Standards Institute. MI00-S22 Performance standards for antimicrobial susceptibility tes- ting; Eleventh informational supplement [ D ]. Wayne, PA: Clinical and Laboratory StandardsInstitute, 2012.
  • 5Beloborodova N V, Kuznetsova S T, Popov D A, et al. Clinical experience with the treatment of severe nosocomi- al infections by inhibitor-protected 3rd generation cepha- losporin cefoperazone/sulbactam [ J ]. Antibiot Khimioter, 2005,50(4) :33-40.
  • 6刘国成,柯红,刘刚,崔洁,王宏斌.头孢哌酮及不同配比头孢哌酮/舒巴坦的体外抗菌活性研究[J].中国药业,2007,16(7):3-4. 被引量:5
  • 7周冠宇,康梅,叶慧,吕晓菊.头孢哌酮/舒巴坦(2∶1)治疗产ESBLs大肠埃希菌感染的临床疗效分析[J].四川大学学报(医学版),2015,46(1):153-154. 被引量:7
  • 8胡继红,张楠,高振祥,高屹,张然,艾效曼,许宏涛,陶凤荣,宣天芝,胡云建.头孢哌酮-舒巴坦药敏纸片中舒巴坦量对药敏结果的影响[J].中华检验医学杂志,2010,33(3):231-235. 被引量:19

二级参考文献29

  • 1方向群,刘又宁,王睿,陈迁,李勇,陈孟莉,赵志坚.头孢哌酮/舒巴坦体外抗菌活性的研究[J].中国临床药理学与治疗学,1996,1(1):8-12. 被引量:1
  • 2李娅娟,刘蓬蓬,李萍,孙伟伟,郝晓佳.头孢哌酮/舒巴坦对革兰阴性菌的抗菌活性[J].中华医院感染学杂志,2006,16(5):554-556. 被引量:40
  • 3王辉,郭萍,孙宏莉,杨启文,陈民钧,朱元珏,徐英春,谢秀丽.碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J].中华检验医学杂志,2006,29(12):1066-1073. 被引量:237
  • 4卫生部合理用药专家委员会.中国医师药师临床用药指南.重庆:重庆出版社,2009:103-105.
  • 5Clinnical and Laboratory Standards Institute. M7-A7 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard. Wayne, PA : Clinical and Laboratory Standardslnstitute ,2006.
  • 6Barry AL, Jones RN. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. J Clin Microbial,1988, 26 : 13-17.
  • 7Clinnical and Laboratory Standards Institute. M2-A9 Performance standards for antimicrobial disk susceptibility tests-Ninth edition; Approved standard. Wayne, PA : Clinical and Laboratory Standardslnstitute, 2006.
  • 8Clinnical and Laboratory Standards Institute. M100-S18 Performance standards for antimicrobial susceptibility testing; Eteenth informational supplement. Wayne, PA: Clinical and Laboratory Standardslnstitute ,2008.
  • 9Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev, 2007,20: 391- 408.
  • 10Higgins PG, Wisplinghoff H, Stefanik D, et al. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother, 2004, 48: 1586-1592.

共引文献686

同被引文献70

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部